Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an immunotherapy drug called durvalumab, research has shown. Jörg ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

(Reuters) -Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung ...

Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle ...